High dose chemotherapy combined with peripheral blood stem cell transplantation (PBSCT) in the treatment of patients with small cell lung cancer
- VernacularTitle:外周血干细胞移植（PBSCT）结合高剂量化疗治疗小细胞肺癌
- Author:
Yunhua BAO
1
;
Hang SU
;
Ge SHEN
;
Xiaochao YUAN
;
Hongjun GAO
;
Wuwei YANG
Author Information
1. Department of Medical Oncology (Division 1), 307 Hospital
- From:
Chinese Journal of Lung Cancer
2001;4(3):184-187
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effect and safety of PBSCT combined with high dose chemotherapy in the treatment of small cell lung cancer(SCLC). Methods From March, 1994 to June, 1999, high dose chemotherapy combined with PBSCT was carried out in 20 patients with SCLC. Eight patients were in CR status while twelve patients were for salvaging therapy. Allo-PBSCT was performed in 1 patient and Auto-PBSCT in 19 patients. After mobilization of stem cell, mononeuclear cell (MNC) was collected for ≥3.0×108／kg, CD34＋ cell≥2.0×106／kg. The high dose chemotherapy included carboplatin 350?mg／m2×3 days, VP-16 120?mg／m2×5 days, and E-ADM 40?mg／m2×2 days. Results Encouraging results were achieved in 8 patients who were in CR status. Seven of the eight patients survived after Auto-PBSCT. One patients survived more than 1 year, 4 cases over 2 years, and 3 cases over 3 years. Of the 3 patients, 2 survived more than 4 years. In the group of salvaging therapy, response was good, however there was no long-term survival and median remission time was only 3.5 months. Conclusion High dose chemotherapy combined with PBSCT in the treatment of SCLC with CR status is feasible and safe, although the side effects are severe too. It is worth further studying on clinical practice.
